Fenfluramine: Fenfluramine was withdrawn from market as an appetite suppressant in 1997 due to cardiotoxicity (valvular heart disease and pulmonary hypertension). Reintroduced in 2020 for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome at lower therapeutic doses. Available only
Related pages